key: cord-0811631-wrdv6ic8
authors: Kukull, Benjamin; Shakir, Salika M.; Hanson, Kimberly E.
title: Performance of Non-Nasopharyngeal Sample Types for Molecular Detection of SARS-CoV-2
date: 2022-02-22
journal: Clin Lab Med
DOI: 10.1016/j.cll.2022.02.002
sha: 02daab4ae140f653cbb187001f07c0d825e56b72
doc_id: 811631
cord_uid: wrdv6ic8

Nasopharyngeal swabs have historically been considered the preferred specimen type for detection of respiratory viruses, including SARS-CoV-2. However, in response to a global pandemic with shortages of swabs and specimen transport media, limited access to qualified health-care personnel, and needs for large-scale testing in non-medical settings, alternative sample types have been validated for COVID-19 diagnosis. The purpose of this review is to highlight the diagnostic accuracy and clinical utility of non-nasopharyngeal respiratory samples for SARS-CoV-2 molecular diagnostic testing.

COVID-19 is predominantly a respiratory disease characterized by a dysregulated inflammatory response to a viral infection with presentations ranging from asymptomatic to multi-organ failure and death. The tropism of SARS-CoV-2, the virus that causes COVID-19, for various tissues is conferred by the widely expressed surface proteins, angiotensin-converting enzyme 2 (ACE2) J o u r n a l P r e -p r o o f and transmembrane serine protease 2 (TMPRSS2), which function as the receptor and coreceptor for cell entry, respectively. ACE2 is present on various cells of the respiratory tract, gastrointestinal (GI) tract, vasculature, and on epithelial cells of various other organs 1 . Due to the potential for multi-organ system involvement and concerns for viral transmissibility, many studies have looked for detectable SARS-CoV-2 RNA in a variety of different body sites. Here, we review the findings and clinical utility of SARS-CoV-2 nucleic acid detection in commonly tested non-nasopharyngeal specimens.

Nasopharyngeal swab (NPS) collection was initially assumed to be the preferred specimen type for SARS-CoV-2 detection. However, NPS collection is relatively invasive, requires trained health-care workers wearing personal protective equipment (PPE) and is subject to sampling error. In addition, dedicated NP swabs were in short supply during the pandemic. Consequently, alternative, non-NP upper respiratory tract (URT) sampling approaches including use of anterior nares (AN) swabs, mid-turbinate (MT) swabs, oropharyngeal (OP) swabs, and saliva were explored to mitigate one or more of the challenges associated with NPS collection (Table 1) .

Saliva was noted to be a promising specimen type early in the pandemic because SARS-CoV-2 was shown to be reproducibly detectable in the oral secretions of infected individuals, it is a noninvasive sample type that requires minimal supervision to obtain, and collection potentially minimizes health-care personnel exposure to infectious aerosols. In addition, saliva reduces the J o u r n a l P r e -p r o o f need for swabs and transport media. However, saliva is a complex matrix that can be difficult to work with in the clinical laboratory. Automated sample-to-result platforms designed for swab collection tubes may not be amenable to use with saliva samples and saliva may require heat or chemical inactivation prior to testing. 2

Viral load is generally highest in saliva within the first week of infection [3] [4] [5] 6 . Of note, saliva performed better than NPS in some studies highlighting the limitation of NPS as the gold standard 5, 7, 8 . Test characteristics varied substantially across different studies comparing saliva to NPS likely as a result of variability in the timing of testing relative to infection onset, severity of illness and efficiency of nucleic acid extraction and amplification.

Several different saliva collection methods have been assessed including passive drool/spit, coughed or deep-throat saliva, oral rinses, and fluid from oral cavity swabs. Saliva tests authorized by the FDA for emergency use require collection tubes with stabilization or inactivation buffers. However, several studies have demonstrated high SARS-CoV-2 RNA J o u r n a l P r e -p r o o f stability in saliva collected in tubes without these additives which may simplify specimen collection and reduce cost 9,10 .

Recent meta-analyses reported that drool or spit protocols had an overall positive detection rate of 86% (95% CI 78-92%) compared to 95% for NPS (95% CI 93-97%) and was superior to oral fluid collected by swabs from the gumline 2 .

Studies comparing coughed or deep-throat saliva had a positive detection rate of 94% compared to NPS, suggesting that these specimens may contain more virus than drool/spit saliva 11,12 . However, forced cough requires use of PPE to protect health care workers against potential infectious aerosols. Saliva that is excessively mucoid may lead to increased pipetting errors on automated systems necessitating a dilution or pretreatment/chemical digestion of the samples.

Studies have shown comparable positivity and stability between undiluted or diluted saliva samples 2 .

Few studies have evaluated oral rinses or gargles for SARS-CoV-2 detection. Saline gargles were suggested for hospitalized patients that were unable to produce sputum and for those patients that were unable to produce sufficient amounts of saliva 13 . Saline gargles appear to have comparable sensitivity to NPS collections for symptomatic patients 14, 15 . In one study, the sensitivity and specificity of saline gargle was observed to be more than 90% and 98%, respectively compared to NPS 14 . In contrast, another study reported a reduced sensitivity (63%) for oral rinses versus undiluted saliva (94.1%) relative to NPS. These studies differed in J o u r n a l P r e -p r o o f collection and testing methods. Oral rinses or gargles may be easier to collect than other forms of saliva, but additional data is required before this approach can be recommended.

Host factors have also been shown to impact SARS CoV-2 test performance.

Symptomatic and asymptomatic individuals infected with SARS-CoV-2 are thought to harbor similar amounts of virus. However, paired comparisons of saliva to NPS for the detection of SARS-CoV-2 RNA in symptomatic and asymptomatic individuals have produced incongruent results potentially as a result of the timing of testing relative to symptom onset. One metaanalysis demonstrated high and comparable sensitivities of saliva in symptomatic and asymptomatic individuals (88% vs. 87%, respectively) while NPS demonstrated higher sensitivity in symptomatic (96%) versus asymptomatic populations (73%) 2 .

Relatively few saliva studies have been performed in the pediatric population and these reports differ widely in terms of sample size, collection, and testing methods 2, 16 . The most robust studies, however, demonstrate comparable sensitivities between saliva and NPS in children (~82% vs. 87%, respectively) 17, 18 . Overall, the subset of pediatric studies suggests that both NP swab and saliva are acceptable sample types.

J o u r n a l P r e -p r o o f Nasal swabs, when swabs are available, are also an attractive alternative to NPS because they are less invasive and can be collected by the patient. Nasal specimens are approved for use with many commercially available NAATs, but there are conflicting data on their test performance compared to NPS. Nasal swab specimens (including AN and MT) are generally obtained from both nares. The CDC's interim guidelines for COVID-19 clinical specimens 19 differentiates between AN and MT collection by the distance of swab insertion into the nostril, but these terms are often used interchangeably in studies comparing their performance to NPS.

A recent meta-analysis showed that nasal swabs (either AN or MT) had a lower positive detection rate of 82% (95% CI 73-90%) compared to 98% (95% CI 96-100%) for NPS, and there was modest agreement (79%) between the two specimen types. Detection with nasal swabs was highest in individuals with symptoms ≤ 7 days (88% [95% CI 74-95%]) 2 .

As observed with saliva collection, substantial heterogeneity was observed in studies comparing nasal and NPS test performance. In addition to the timing of testing, swab type has also been shown to affect test sensitivity. Specifically, foam or flocked nasal swabs performed better than unflocked or polyester swab specimens (percent positivity 90%, (95% CI 81-97%) vs 77% (95% CI 55-93%), respectively) 20,21 , while the person collecting the sample (self vs. healthcare worker) and use of transport media (dry swab vs. diluted) do not appear to impact detection rates 20,21 2 .

A meta-analysis of OP swab and NPS samples in symptomatic patients found similar positivity rates (84% [95% CI 57-100%] vs. 88% [95% CI 73-98%], respectively), but the overall agreement between the two sample types was only 68% (95% CI 36-93%) 2 . Two additional J o u r n a l P r e -p r o o f meta-analyses showed that combining both OP and AN swab in a single collection tube improves the rate of SARS-CoV-2 detection by molecular methods (sensitivity 97% and specificity 99%) 2,22 . In addition, supervised self-collected OP/AN swabs had comparable sensitivity to HCWcollected OP/AN swabs using three different molecular testing platforms 23 .

The lower respiratory tract (LRT) is considered to be the most sensitive anatomic site for SARS-CoV-2 RNA detection 24 , possibly due to reports suggesting that higher levels of RNA are present in this anatomic compartment 25, 26 . However, it is important to note that this observation may be biased by the fact that severe presentations, which presumably are associated with higher virion burden, were more likely to have LRT testing performed. Viral RNA loads and infectious particles peak in the first week of infection in the LRT (Figure 1 ) [27] [28] [29] , but the shedding of viral RNA and infectious virus particles can be prolonged in this compartment 25, 28 . Prolonged shedding is thought to be more pronounced in severe disease and in the immunocompromised.

These patients may yield positive test results for several months beyond the resolution of symptoms 25, 26, 30 , and the clinical and infection control significance of this is not fully known.

Additional limitations of LRT testing include the need for clinical laboratories to validate additional sample types that may not be covered under emergency use authorizations (EUAs) for commercially available SARS-CoV-2 NAATs. Common LRT sampling strategies are also associated with risk for aerosol generation and some (e.g., bronchoscopy) are invasive.

Few studies have directly compared the diagnostic yield of various LRT specimen types to one another or to NPS collected from the same patient at the time. In one study of >1000 patients J o u r n a l P r e -p r o o f where exposure history, symptoms, and radiology were used as a reference method to confirm COVID-19, the highest viral RNA detection rates were in bronchoalveolar lavage specimens (93%), followed by sputum (72%) and then nasal swabs (63%) 31 .

Sputum can be collected during voluntary expectoration or by induction. However, COVID-19 patients may not have a productive cough and sputum induction has generally been avoided due to risk for generating infectious aerosols. Thick mucus might also add to the difficulty in isolating nucleic acids in some specimens. Classic nucleic acid isolation techniques in sputum have included treatments with reducing agents and mucolytic enzymes to reduce viscosity and increase nucleic acid yield. Manufacturer-approved sterile collection tubes should also be used for molecular testing, as certain synthetic polymers can bind nucleic acid and interfere with the yield of extraction.

ETA specimens can be acquired from intubated patients or through a tracheostomy tube. To collect this specimen type, a catheter is placed through the endotracheal tube and secretions are usually aspirated into a sterile pre-attached specimen trap. ETAs are sometimes collected when more invasive testing strategies are not possible and may be less likely to produce aerosols compared to bronchoscopy. ETA samples are thought to have similar sensitivities compared sputum, but relatively little performance data for ETA exists 31, 32 .

J o u r n a l P r e -p r o o f BAL sampling is performed during minimally flexible bronchoscopy by instilling a specific amount of saline and aspirating this volume for testing 33 . For example, a lavage volume of 100 mL samples approximately 1.5-3.0% of the lung, or approximately one million alveoli. BAL may be performed with or without established intubation and many centers tried to avoid these procedures due to aerosol generation. However, reports of increased SARS-CoV-2 detection sensitivity of this specimen type provide diagnostic rationale especially in the case of pneumonia with negative upper respiratory tract testing and high radiologic and/or clinical suspicion of COVID-19 34 . BAL sampling has been shown to have the highest rate of detection compared to all other samples in systematic comparison studies as well as in late clinical detection and persistent disease 26, 31 . BAL testing may also be particularly useful when co-infections need be ruled out with high confidence.

Due to convenience, upper respiratory tract (URT) testing is the preferred as the first line-test.

However, LRT testing may also be useful, especially when URT testing is negative but a high clinical suspicion for COVID-19 pneumonia remains. Current IDSA guidelines recommend collection of NPS, MTS, ANS, saliva, or a combined AN/OP swab(s) rather than OPS alone as a first test for all symptomatic persons 35 .

Following the respiratory tract, the GI system is the next most affected organ system by COVID-19, which is believed to be related to the viral tropism of various cell types in the GI tract 1 .

Several studies estimate that GI symptoms in COVID-19 patients may be present in J o u r n a l P r e -p r o o f approximately 10-50% of patients 36, 37 . The presentation of GI symptoms ranges from asymptomatic to severe disturbances, which in some cases is reported independent of the severity of respiratory disease 28 . SARS-CoV-2 RNA has been detected from various GI specimens including gastric lavage stool, and ano-rectal swabs, but stool is the most reported specimen type. Certainly, collection and RT-PCR needs to be carefully standardized to ensure meaningful data in this highly variable sample type. There are many natural constituents of stool that degrade viral RNA and inhibit PCR reactions, including degradative enzymes, bile salts, and dietary polysaccharides.

Despite the natural challenges with this specimen type, viral RNA has been detected in stool over a broad timeframe regardless of GI symptoms or severity of disease 25, 26 . Interestingly, the detection of viral RNA in stool does not seem to correlate with respiratory viral RNA detection or vice versa 25, 28, 38 . There is significant heterogeneity between studies and meta-analyses with regards to clinical sensitivity (approximate range: 30-60%) and detection timeframes (Figure 1) employed in several public health surveillance strategies 39 . This approach to a massively "pooled" specimen may be useful for predicting outbreaks on the population level.

As with stool, meta-analyses of the detection of SARS-CoV-2 RNA in serum or plasma have significant heterogeneity and this specimen type is not recommended for diagnostic testing 19, 40 .When compared to all respiratory sample types, the clinical sensitivity of blood specimens for COVID-19 infection is consistently much lower (~0-45%), and positive detection appears to correlate with disease severity and mortality in a few reports 26, 29, 41 . When testing blood, it is important to note that molecular tests should exclude samples with residual, well-described, and ubiquitous PCR inhibitors from their protocols, such as heme and heparin. Viral RNA detection surprisingly has been detected up to 60 days in serum 25 , but most studies reporting an average detection timeframe of 3-18 days (Figure 1) 26 . Despite the potential prolonged detection of viral RNA in these specimen types, no live virus has been successfully isolated from serum in these reports 26, 28 . Recently, a massive study of 258,000 blood donations showed very infrequent detection of SARS-CoV-2 RNA (1.16/100,000), and no infectivity was demonstrated in cell culture 42 . Considering an extremely low risk of COVID-19 transmission from blood, FDA does not currently require screening routine asymptomatic blood donors for SARS-CoV-2 or after 14 days of resolution of COVID-19 symptoms 43 .

J o u r n a l P r e -p r o o f SARS-CoV-2 testing have been performed on the body fluids below, but data currently exist as case reports without paired comparisons to a reference method or standardized molecular detection methods. None of the fluids discussed below are currently considered clinically useful for the detection of SARS-CoV-2 (Table 1) .

Cerebrospinal fluid (CSF) testing has been reported in several studies and analyzed in metaanalyses, with rare reports detected viral RNA 26 . It is not clear if these instances represent a true positive, viremia with CSF blood contamination, or breach of the blood-brain barrier due to systemic inflammation, or other vascular pathology. There appears to be no clinical indication for CSF sampling in COVID-19 patients, yet some laboratories may still offer this testing as a validated specimen type. There is a similar scenario with urine, where little to no detection has been reported 44, 45 . Detected viral RNA could represent primary renal involvement or viremia with widespread vascular pathology. Of note, ACE2 and TMPRSS2 are co-expressed in renal tubules and podocytes 46 , and primary COVID 19-associated kidney pathology has been proposed 47 . There is also inconclusive or conflicting evidence for the true involvement of SARS-CoV-2 in amniotic fluid, breast milk, conjunctival secretions, semen, and vaginal secretions 26 .

SARS-CoV-2 viral RNA shedding is temporally dynamic and differs between respiratory and distant anatomic sites. Standardized collection processes and appropriate testing rationale are essential, regardless of specimen type. The vast majority of test performance data comes from assessments of various URT specimen types. URT samples are easy to obtain and accurate in J o u r n a l P r e -p r o o f comparison to NP testing, but it should be noted that NP testing is an imperfect gold standard and there may be circumstances where alternatives are preferred. There is also clear utility in testing the lower respiratory tract, especially when URT testing is negative and there is high clinical suspicion for COVID-19 pneumonia. Stool testing is not as clinically sensitive in COVID-19 patients as respiratory specimens, but studies of sewage show continual promise as population-level screening tool. The presence of SARS-CoV-2 viral RNA in blood and other body fluids appears to be transient in the most severely ill patients, shows great variability, and should not be performed to track disease progression. A shared knowledge of the limitations of molecular tests is also clinically essential as we face a landscape of novel variants with unpredictable testing parameters. Constant adaptation to these viral dynamics will be required in addition to higher quality data for emerging detection technologies. [25] [26] [27] 29 . This data has not been standardized between studies. The peak Ct range (black area), average duration of detection (arrowhead), and total reported detectable range (black + vertical line areas) of SARS-CoV-2 RNA are averages of published data from the same references and were inferred in these cases from studies with serial RT-PCR testing and reported Ct values for these specimen types. Upper and lower respiratory tract specimens peak most often in the first week, while the peak range for non-respiratory specimens is not well-defined. Note that detection of viral RNA in blood and urine is infrequent, and average and extreme ranges overlap. Specific specimen types were omitted due to a relative lack of quality, high power data for meaningful comparisons. URT = upper respiratory tract; LRT = lower respiratory tract.

Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2. Frontiers in medicine

Performance of Saliva, Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular Detection: A Systematic Review and Meta-analysis

Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID-19 infection

Saliva as a Noninvasive Specimen for Detection of SARS-CoV-2

Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2

Comparison of Saliva and Nasopharyngeal Swab Nucleic Acid Amplification Testing for Detection of SARS-CoV-2: A Systematic Review and Meta-analysis

Self-Collected Anterior Nasal and Saliva Specimens versus Healthcare Worker-Collected Nasopharyngeal Swabs for the Molecular Detection of SARS-CoV-2

Self-Collected Oral Fluid and Nasal Swab Specimens Demonstrate Comparable Sensitivity to Clinician-Collected Nasopharyngeal Swab Specimens for the Detection of SARS-CoV-2

Evaluation of Specimen Types and Saliva Stabilization Solutions for SARS-CoV-2 Testing

Stability of SARS-CoV-2 RNA in Nonsupplemented Saliva

A Direct Comparison of Enhanced Saliva to Nasopharyngeal Swab for the Detection of SARS-CoV-2 in Symptomatic Patients

Comparing Nasopharyngeal Swab and Early Morning Saliva for the Identification of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Gargle Lavage as a Safe and Sensitive Alternative to Swab Samples to Diagnose COVID-19: A Case Report in Japan

Self-Collected Saline Gargle Samples as an Alternative to Health Care Worker-Collected Nasopharyngeal Swabs for COVID-19 Diagnosis in Outpatients

Detection of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) in outpatients: A multicenter comparison of selfcollected saline gargle, oral swab, and combined oral-anterior nasal swab to a provider collected nasopharyngeal swab

Saliva is not a useful diagnostic specimen in children with Coronavirus Disease

Saliva for molecular detection of SARS-CoV-2 in school-age children

Saliva Is a Promising Alternative Specimen for the Detection of SARS-CoV-2 in Children and Adults

Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for COVID-19

Swabs Collected by Patients or Health Care Workers for SARS-CoV-2 Testing

A comparison of health care worker-collected foam and polyester nasal swabs in convalescent COVID-19 patients

Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis

A combined oropharyngeal/nares swab is a suitable alternative to nasopharyngeal swabs for the detection of SARS-CoV-2

Performance Characteristics of Severe Acute Respiratory Syndrome Coronavirus 2 RT-PCR Tests in a Single Health System: Analysis of >10,000 Results from Three Different Assays

SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. The Lancet Microbe

Towards a sensitive and accurate interpretation of molecular testing for SARS-CoV-2: a rapid review of 264 studies. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

SARS-CoV-2 detection, viral load and infectivity over the course of an infection

Virological assessment of hospitalized patients with COVID-2019

An Overview of the Temporal Shedding of SARS-CoV-2 RNA in Clinical Specimens

Persistent Detection and Infectious Potential of SARS-CoV-2 Virus in Clinical Specimens from COVID-19 Patients

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

SARS-CoV-2 Viral Load in Clinical Samples from Critically Ill Patients. American journal of respiratory and critical care medicine

Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19)

Negative Nasopharyngeal and Oropharyngeal Swabs Do Not Rule Out COVID-19

Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing

Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis

Gastrointestinal involvement in COVID-19: a systematic review and metaanalysis

Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission

Wastewater Surveillance System (NWSS)

SARS-CoV-2 viral load is associated with increased disease severity and mortality

Minipool testing for SARS-CoV-2 RNA in United States blood donors

Updated Information for Blood Establishments Regarding the COVID-19

Detection profile of SARS-CoV-2 using RT-PCR in different types of clinical specimens: A systematic review and meta-analysis

COVID-19 (SARS-CoV-2) in Non-Airborne body fluids: A systematic review & Meta-analysis

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Frontiers of medicine

COVID-19-Associated Collapsing Glomerulopathy: An Emerging Entity